Edward C. Lant

Edward C. Lant

Auto-generated profile, based on publicly available information

Edward C. Lant

Department of Chemistry

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Chemical Science
Verified
Journal Article
Open access
PDF file
EAElizabeth J. Anthony
Elizabeth J. Anthony
EBElizabeth M. Bolitho
Elizabeth M. Bolitho
HBHannah E. Bridgewater
Hannah E. Bridgewater
OCOliver W. L. Carter
Oliver W. L. Carter
JDJane M. Donnelly
Jane M. Donnelly
ZZZijin Zhang
Zijin Zhang
Metals play vital roles in nutrients and medicines and provide chemical functionalities that are not accessible to purely organic compounds. At least 10 metals are essential for human life and about 46 other non-essential metals (including radionuclides) are also used in drug therapies and diagnostic agents. These include platinum drugs (in 50% of cancer chemotherapies), lithium (bipolar disorders), silver (antimicrobials), and bismuth (broad-spectrum antibiotics). While the quest for novel and better drugs is now as urgent as ever, drug discovery and development pipelines established for organic drugs and based on target identification and high-throughput screening of compound libraries are less effective when applied to metallodrugs. Metallodrugs are often prodrugs which undergo activation by ligand substitution or redox reactions, and are multi-targeting, all of which need to be considered when establishing structure–activity relationships. We focus on early-stage in vitro drug discovery, highlighting the challenges of evaluating anticancer, antimicrobial and antiviral metallo-pharmacophores in cultured cells, and identifying their targets. We highlight advances in the application of metal-specific techniques that can assist the preclinical development, including synchrotron X-ray spectro(micro)scopy, luminescence, and mass spectrometry-based methods, combined with proteomic and genomic (metallomic) approaches. A deeper understanding of the behavior of metals and metallodrugs in biological systems is not only key to the design of novel agents with unique mechanisms of action, but also to new understanding of clinically-established drugs.

31 August 2022 in Dalton Transactions
Verified
Journal Article
Open access
PDF file
ASAlexandra Sink
Alexandra Sink
SBSamya Banerjee
Samya Banerjee
JWJuliusz Wolny
Juliusz Wolny
CICinzia Imberti
Cinzia Imberti
ELEdward C. Lant
Edward C. Lant
PSPeter J. Sadler
Peter J. Sadler
The roles of hydrolysis, concerted proton transfer, and methanol in ring methyl C–H activation via a Rh(i)–fulvene intermediate are elucidated.

7 May 2025 in ChemCatChem
Verified
Journal Article
Open access
ELEdward C. Lant
Edward C. Lant
RNRussell J. Needham
Russell J. Needham
ZZZijin Zhang
Zijin Zhang
JCJames Paul Charles Coverdale
James Paul Charles Coverdale
GCGuy J. Clarkson
Guy J. Clarkson
PSPeter J. Sadler
Peter J. Sadler
We report the synthesis and characterization of ten novel half‐sandwich Rh(III) azopyridine complexes as potential anticancer agents, with the general formula [(η5‐Cpx)Rh(4‐R2‐phenylazopy‐5‐R1)Cl]PF6, where Cpx = Cp*, CpxPh or CpxPhPh, R1 = H, Br, or CF3, and R2 = H, OH or NMe2. X‐ray crystallographic data for complex 2 (R1 = Br, R2 = OH, Cpx = CpxPh) and complex 3 (R1 = CF3, R2 = OH, Cpx = CpxPh) confirm their typical half‐sandwich “piano‐stool” geometry. The substituents have a major influence on the cytotoxicity of these complexes toward human ovarian (A2780 and cisplatin‐resistant A2780cis), lung (A549) and prostate (PC‐3) cancer cells, and non‐cancerous human lung fibroblasts (MRC‐5). Potencies range from sub‐micromolar to inactive (>50 µM). They were non‐cross‐resistant with cisplatin, and complex 9 (R1 = H, R2 = NMe2, Cpx = Cp*) showed some selectivity (>3x) for A549 cancer cells versus normal cells. The highly active, lipophilic complex 2 was strongly accumulated by cells and catalyzed the oxidation of NADH (reduced nicotinamide adenine dinucleotide) to NAD+, and GSH (glutathione) to GSSG. Notably, complex 2 is almost an order of magnitude less toxic toward zebrafish in vivo than cisplatin, despite being 10‐fold more active in A549 cells. These studies demonstrate how the chemical and biological activities of this series of half‐sandwich organorhodium(III) complexes can be finely tuned by the choice of substituents on the cyclopentadienyl and azopyridine ligands. The complexes appear to have an unusual mechanism of anticancer activity, associated not only with Rh(III) but also with the phenylazopyridine, cyclopentadienyl, and the chlorido ligands.

13 March 2026 in Inorganic Chemistry
Verified
Journal Article
Open access
ELEdward C. Lant
Edward C. Lant
AJArchana C. Jadhav
Archana C. Jadhav
ASAnnabel Sumeray
Annabel Sumeray
GTGustavo F. Trindade
Gustavo F. Trindade
LCLuca Craciunescu
Luca Craciunescu
PSPeter J. Sadler
Peter J. Sadler
An integrated multimodal imaging workflow of cryogenic super-resolution fluorescence microscopy and soft X-ray tomography, Orbitrap secondary ion mass spectrometry, and inductively coupled plasma-mass spectrometry has revealed the unexpected targeting of a half-sandwich cyclopentadienyl Rh(III) phenylazopyridine anticancer complex to cellular lipid membranes and lipid droplets. The complex accumulates in plasma membranes with a surprisingly intense switch-on luminescence in living cancer cells, drives remodeling of lipid droplet architecture, and penetrates deeply into lipid-rich tissue environments. DFT modeling shows strong supramolecular interactions between the complex and glycerophosphorylcholine lipids.